Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

▤ Summary

Lilly received a positive CHMP opinion for Jaypirca in the European Union for adults with chronic lymphocytic leukemia across all lines of therapy. The decision expands the potential use of pirtobrutinib beyond its current scope and moves the drug one step closer to EU marketing authorization. Lilly also filed the same data package with the U.S. FDA, with a decision expected in the second half of 2026. The announcement centers on clinical trial results, regulatory progress, and the commercial expansion of an approved oncology therapy.

▦ Linked Companies